Ekaterini Siomou1, Athanasios Gkoutsias2, Anastasios Serbis2, Konstantinos Kollios3, Nikolaos Chaliasos2, Veronique Frémeaux-Bacchi4. 1. Department of Pediatrics, Ioannina University Hospital, Stavros Niarchos Avenue, GR-45 500, Ioannina, Greece. eksiomou@yahoo.gr. 2. Department of Pediatrics, Ioannina University Hospital, Stavros Niarchos Avenue, GR-45 500, Ioannina, Greece. 3. Third Department of Pediatrics, Aristotle University School of Medicine, Thessaloniki, Greece. 4. Service d'Immunologie Biologique Hôpital Européen Georges Pompidou, Paris, France.
Abstract
BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is frequently associated with gene mutations in complement-regulatory proteins and activators. Different complement C3 gene mutations have been associated with different outcomes in aHUS. CASE-DIAGNOSIS/TREATMENT: We report the case of a 21-year-old male with a C3 heterozygous gene mutation (p.Ile1157Thr) who developed aHUS at the age of 10 months and had six relapses, the last at the age of 14.5 years. Each relapse was characterized by an apparent predominance of hematological manifestations with milder renal involvement and was followed by complete recovery, with creatinine values and hematological parameters usually recovering after the 3rd to 6th day of hospitalization. The patient was treated with plasma infusion, apart from the initial and the last episode, when dialysis was needed. Twenty years after the onset, he retains normal renal function, with no proteinuria or hypertension. One similar case of highly recurrent aHUS carrying the same C3 mutation as our patient with recovery of renal function has been previously reported. CONCLUSIONS: We further support that aHUS associated with the p.Ile1157Thr C3 mutation may be highly recurrent, but with recovered renal function. The prevalent p.Ile1157Thr C3 gene mutation has variable disease manifestations and both severe and milder renal phenotypes have been found.
BACKGROUND:Atypical hemolytic uremic syndrome (aHUS) is frequently associated with gene mutations in complement-regulatory proteins and activators. Different complement C3 gene mutations have been associated with different outcomes in aHUS. CASE-DIAGNOSIS/TREATMENT: We report the case of a 21-year-old male with a C3 heterozygous gene mutation (p.Ile1157Thr) who developed aHUS at the age of 10 months and had six relapses, the last at the age of 14.5 years. Each relapse was characterized by an apparent predominance of hematological manifestations with milder renal involvement and was followed by complete recovery, with creatinine values and hematological parameters usually recovering after the 3rd to 6th day of hospitalization. The patient was treated with plasma infusion, apart from the initial and the last episode, when dialysis was needed. Twenty years after the onset, he retains normal renal function, with no proteinuria or hypertension. One similar case of highly recurrent aHUS carrying the same C3 mutation as our patient with recovery of renal function has been previously reported. CONCLUSIONS: We further support that aHUS associated with the p.Ile1157Thr C3 mutation may be highly recurrent, but with recovered renal function. The prevalent p.Ile1157Thr C3 gene mutation has variable disease manifestations and both severe and milder renal phenotypes have been found.
Authors: Carla M Nester; Thomas Barbour; Santiago Rodriquez de Cordoba; Marie Agnes Dragon-Durey; Veronique Fremeaux-Bacchi; Tim H J Goodship; David Kavanagh; Marina Noris; Matthew Pickering; Pilar Sanchez-Corral; Christine Skerka; Peter Zipfel; Richard J H Smith Journal: Mol Immunol Date: 2015-04-03 Impact factor: 4.407
Authors: Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi Journal: Clin J Am Soc Nephrol Date: 2010-07-01 Impact factor: 8.237
Authors: Elizabeth C Schramm; Lubka T Roumenina; Tania Rybkine; Sophie Chauvet; Paula Vieira-Martins; Christophe Hue; Tara Maga; Elisabetta Valoti; Valerie Wilson; Sakari Jokiranta; Richard J H Smith; Marina Noris; Tim Goodship; John P Atkinson; Veronique Fremeaux-Bacchi Journal: Blood Date: 2015-01-21 Impact factor: 22.113
Authors: Mihály Józsi; Christoph Licht; Stefanie Strobel; Svante L H Zipfel; Heiko Richter; Stefan Heinen; Peter F Zipfel; Christine Skerka Journal: Blood Date: 2007-11-15 Impact factor: 22.113
Authors: Veronique Frémeaux-Bacchi; Elizabeth C Miller; M Kathryn Liszewski; Lisa Strain; Jacques Blouin; Alison L Brown; Nadeem Moghal; Bernard S Kaplan; Robert A Weiss; Karl Lhotta; Gaurav Kapur; Tej Mattoo; Hubert Nivet; William Wong; Sophie Gie; Bruno Hurault de Ligny; Michel Fischbach; Ritu Gupta; Richard Hauhart; Vincent Meunier; Chantal Loirat; Marie-Agnès Dragon-Durey; Wolf H Fridman; Bert J C Janssen; Timothy H J Goodship; John P Atkinson Journal: Blood Date: 2008-09-16 Impact factor: 22.113
Authors: Wolfgang Winnicki; Peter Pichler; Karl Mechtler; Richard Imre; Ines Steinmacher; Gürkan Sengölge; Daniela Knafl; Georg Beilhack; Ludwig Wagner Journal: PeerJ Date: 2019-12-16 Impact factor: 2.984
Authors: Javier Lumbreras; Marta Subias; Natalia Espinosa; Juana María Ferrer; Emilia Arjona; Santiago Rodríguez de Córdoba Journal: Front Immunol Date: 2020-07-16 Impact factor: 7.561
Authors: Ebun Omoyinmi; Iman Mohamoud; Kimberly Gilmour; Paul A Brogan; Despina Eleftheriou Journal: Front Immunol Date: 2018-11-01 Impact factor: 7.561